CSI Market
Sign In | Register

Xenetic Biosciences Inc (XBIO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access XBIO Annual Cash Flow →
Quarterly cash flow trends provide additional context on Xenetic Biosciences Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-1.39
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.06
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Fee Paid On Disposal Of Subsidiaries-
Interest Expense-
Loss On Issuance Of Hybrid Debt Instrument-
Other Research And Development Expense-
Inprocess Research And Development Expense-
Noncash Interest Expense-
Vendor Share Based Payments-
Vendor Sharebased Payments-
Finance Lease Right Of Use Asset Amortization-
Operating Lease Right Of Use Asset Amortization Expense0.03
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Accounts and Other Receivables0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.07
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.02
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.03
Discontinued operations0.00
Net Cash flow from Operating Activities-1.41
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Business Combination Transaction Fees Paid-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Cash Divested from Deconsolidation0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Employees For Issuance Of Common Stock To Employee Benefit Trust-
Proceeds From Issuance Of Units In Offering-
Proceeds From Issuance Or Sale Of Equity-
Net Proceeds From Issuance Of Common Stock And Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.41
Total Cash Flow-1.41
4 historic quarters locked

Sign in to unlock the full Xenetic Biosciences Inc cash flow history.

Sign In Create Free Account

About Xenetic Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001683168-26-006061

Figures are derived from filed reports and may be restated. Historical data is subject to revision.